Batch alignment of mass spectrometry imaging (MSI) metabolome through data integration


Mass spectrometry imaging (MSI) is a critical tool used to investigate tissues and molecules in spatial bioanalysis. Technical challenges in MSI, also known as batch-effects, have proven to impede reliable comparison of data from large-scale studies performed in translational clinical research. 

Meaningful analysis of data generated in large-scale studies is critical for medicine and biology studies. This application note focuses on a batch correction method designed to minimize impedance of batch-effects and allow reliable identification of biological clusters and their comparison.  
Download to learn more about batch alignment through data integration. 

Download Now

Automated approach to quantify single molecule in complex tissues

This application note focuses on an efficient analysis method which enables the quantification of molecules at the single-cell level. Accurate RNA quantification in single molecules is crucial to understand the dynamics of gene expression and regulation. 
In this study, individual molecules were imaged in fixed cells and DNA staining was performed in tumoral areas of the tissue. Analysis results showcase quantification of single cells and provide an understanding of cell-to-cell interactions in cancer cells and other molecules.  
Download to learn more about quantifying single molecules in complex tissues. 

Download Now

QMSI vs. QWBA: evaluating benefits and risks

Knowing when to use Quantitative Mass Spectrometry Imaging (QMSI) instead of Quantitative Whole-Body Autoradiography (QWBA) can make or break a timeline and budget for pharma and biotech companies.

Consider the following key advantages when selecting which technique is right for your drug development program:

QSMI Advantages:

  • Label-free quantification of thousands of analytes
  • Excellent differentiation among parent drugs, metabolites, and other substances
  • Highly specific in quantification by location in tissue

QWBA Advantages:

  • Highly precise quantification capabilities, even at low and high limits of detection
  • Spatial resolution at the cellular level
  • Gold standard technique for the late-stage regulatory distribution studies

Even though QWBA remains the gold standard technique during late stage for regulatory agencies, QMSI is frequently used in support of the autoradiography in certain circumstances.

Further evaluate the benefits and risks associated with each technology.

Download Now

Personalized therapy selection: Investigation of multiple immune-checkpoints

PD1 blockade has changed the immunotherapy approach against solid tumors – prescribing patients’ monoclonal antibody-based therapy yielded positive results. However, the number of patients that benefited was small compared to expectations, and lack of attention paid to immunohistochemistry could be responsible. Understanding the tumor microenvironment with a single biomarker is not accurate enough to predict the interaction of the drug with the site of action, or to predict the effectiveness of the drug for the patient.

In this application note, industry expert, Corinne Ramos, PhD, discusses how understanding the tumor microenvironment (TME) at the biomarker level is not enough to predict the interaction of the drug with the site of action. Her study performs a deep spatial profiling of biomarkers on two baseline non-small cell lung cancer (NSCLC) tissue samples. The population of gene expression was characterized with a focus on a specific region of interest on the tissue where she could draw conclusions on the TME.

Her research walks through:

  • Immune infiltration
  • How phenotype correlates with ICI response
  • T-cell-inflamed gene-expression profiles
  • Immune suppressive pathways that reduce ICI activity
  • Tight immune checkpoint targeting.

Learn why the TME needs to be investigated at the molecular level to accurately prescribe the appropriate therapy.

Download Now

Top 8 Benefits of Mass Spectrometry Imaging Early in Drug Development

Mass spectrometry imaging (MSI) is a groundbreaking technology that provides visuals of complex biological samples to study a drug’s distribution and understand its potential toxicity. MSI can unlock crucial data and give scientists additional insights into drug discovery, diseases, and personalized medicine.

MSI is beneficial in early development and murine models across many therapeutic areas and is especially suited to oncology due to the availability of tissue. With MSI you can:

  • Speed up and optimize the drug discovery process
  • Visualize drug distribution in tissues and tissue sub-compartments
  • Analyze samples for thousands of compounds at once
  • Eliminate sensitivity and chemical alteration concerns
  • Know whether efficacy is possible based on distribution
  • Locate and identify metabolites to understand potential toxicity
  • Improve understanding of pharmacokinetics and pharmacodynamics
  • Save money and provide a competitive development edge

Download our infographic to learn more about the benefits of mass spectrometry imaging in oncology.

Download Now

The Future of Small and Large Molecule Bioanalytics—Today

In bioanalysis, the future of small and large molecules offers exciting prospects for advancements in drug discovery, diagnostics, and therapeutics. With the increase of larger substances, emerging technologies, and new analytical approaches, drug developers are faced with both new opportunities to evaluate complex substances, and new challenges to address. Therefore, it’s important to learn which bioanalysis techniques are right for your drug.

In this white paper, you’ll learn about:

  • Bioanalysis by molecular size
  • Advancements in mass spectrometry
  • Visualization and quantification of drug distribution
  • The era of spatial imaging
  • Novel technologies and adaptions

For more information about emerging technologies revolutionizing the field of bioanalysis, download our whitepaper today.

Download Now

Validating the efficacy of a compound with spatial imaging

With the ever-changing drug development landscape, pharma and biotech companies have the challenging task to quickly and efficiently generate quality and unique data to file an IND. Spatial bioanalysis is a unique solution that can help you achieve this goal, while also enabling strategic and optimized decision making throughout your process.

Download this spatial bioanalysis white paper to gain insights from industry expert, Corinne Ramos, PhD. Discussion points include:

  • Precision medicine development and added value
  • Disease heterogeneity: Why is it? Why is it important? How do we visualize it?

Target discovery and development of composite biomarkers

Download Now